Company: RGBP
Filing Date: 2025-02-24
Form Type: 253G1
Source: 0001493152-25-008067
Chunk: 48

Company: Regen BioPharma Inc
Filing Date: 2025-02-24
Form: 253G1
Chunk 48
---
 Derivative Liability of $1,397,274 and as of September 30, 2023 we had a Derivative Liability of $1,400,000. The decrease in Derivative Liability of approximately 19% is attributable to the recognition by the Company of embedded derivatives on Convertible Notes Payable with an aggregate face value of $350,000 outstanding as of September 30, 2024 as opposed to recognition by the Company of embedded derivatives on Convertible Notes Payable with an aggregate face value of $350,000 outstanding as of September 30, 2023 .

Revenues from continuing operations were $236,560 for the twelve months ended September 30, 2023 and $236,560 for the same period ended 2024. $110,000 of revenue from related parties recognized during the twelve months ended September 30, 2023 and September 30, 2024 consisted of anniversary expense receivable pursuant to a license granted by the Company to Zander Therapeutics, Inc. and minimum royalties recognized during the twelve months ended September 30, 2023 and 2022 respectively pursuant to the same license. $126,560 of revenue recognized during the twelve months ended September 30, 2023 and September 30, 2024 were recognized pursuant to licenses granted to Oncology Pharma,Inc.

The Company recognized an Operating Loss of $689,650 during the twelve months ended September 30, 2023 whereas the Company recognized an Operating Loss of 418,189 for the same period ended 2024. The large disparity in Operating Losses is primarily attributable to $606,237 in Consulting and Professional fees expensed during the period ended 2023. The Company recognized Net Income of $1,156,507 for the twelve months ended September 30, 2023 as opposed to a Net Loss of $867,252 for the same period ended 2034 the difference primarily attributable to the recognition by the Company of Derivative Income of $2,151,755 during the twelve months ended September 30, 2023.

As of September 30, 2024 we had $716 in cash on hand and current liabilities of $5,371,640 such liabilities materially consisting of Accounts Payable, Notes Payable, Convertible Notes Payable, Derivative Liability Recognized, Unearned Income and Accrued Expenses. We feel we will not be able to satisfy our cash requirements over the next twelve months and shall be required to seek additional financing.